BCL2 and Thrombocytopenia: Despite these advances, systemic inhibition of BCL-2 family proteins remains constrained by on-target toxicity, as normal hematopoietic and cardiac cells rely on BCL-xL and BCL-2 for survival, as illustrated by the dose-limiting thrombocytopenia associated with navitoclax (179).